Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.

Rachel PorthTina DeyhimSamantha ZullowLoren G RabinowitzLaurie B GrossbergXavier RoblinStephane PaulAdam S CheifetzKonstantinos Papamichael

Published in: Inflammatory bowel diseases (2024)

In this single-center retrospective study reflecting real-life clinical practice, proactive TDM was associated with increased drug persistence in patients with IBD treated with iv VDZ.

Keyphrases

patients with inflammatory bowel disease
clinical practice

ulcerative colitis

high dose

adverse drug